Replies to post #165708 on Biotech Values

[masterlongevity]

'As long ago as 2006, it was apparent that Genentech (then a partially owned Roche subsidiary) thought highly of this drug, which was obtained from a small biotech company called Tanox i'


actually there was a lot of heated arguments over this, with some people calling it junk ad others pushing strongly for it. the junk guys won for a while as there was already too much to take on with lucentis. i'm glad to see this alive and doing well

[biotech jim]

Looks to me that they are doing a large peripheral blood biomarker survey for complement factor component levels and activation as predictors of responding patients with this factor D blocking antibody, lampalizumab or TNX-234. Probably need this type of data to prove that this is a winner and to make this approvable. Not certain that peripheral blood markers predict what is going on intra-ocularly though. Is this level of efficacy seen (20.4% reduction in GA) clinically meaningful?

I wondered what happened to this program, as the complement factor pathway has been strongly implicated in a variety of inflammatory situations including dry AMD. Took a while for this program to see the light of day, as long trials are needed for determining efficacy. Thanks for posting this.